Evolutionary trend of invasive pneumococcal disease according to serotypes

Aim: To compare epidemiologic,clinical and evolutionary aspects of invasive pneumococcal disease(IPD) in adults in our setting caused by serotypes included in13-valent pneumococcal conjugate vaccine (PCV13) compared to other serotypes Methods: Retrospective study including patients>18years old hospitalized with IPD 01/2007-12/2015. SPSS 18.0 software. Results: 202 samples of IPD,88 caused by serotypes included in PCV13(46.3%).IPD caused by these serotypes affected more patients>65(56.8%)and those who had at least 1comorbidity(68.2%).Most frequent presentation:uncomplicated community-acquired bacterial pneumonia (57.1%). :comorbidities of patients with IPD caused by PCV13 serotypes and evolutionary trend of IPD by serotypes.No statistically significant differences found with other serotypes or with age,type of comorbidities or clinical presentation.36% of the patients with IPD by serotypes included inPCV13 had received the 23Vpolysaccharide vaccine(PPSV23) which also includes these serotypes. Conclusions: Almost half of IPDcases were caused by serotypes included inPCV13.No differences between groups for age,type of comorbidity or clinical presentation.The vaccination coverage in our setting is low,the effectiveness of PPSV23 has been limited.There was a decrease in the incidence rate in both groups from 2011 to 2014. However,there has been a striking increase in the rate of IPD caused by serotypes not included in the PCV13.